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Summary
Members of the SLC20 solute carrier family, PiT1 and PiT2, originally identified as retroviral
receptors, transport inorganic phosphate (Pi) in a Na+-dependent manner. In addition to a
proposed housekeeping role for phosphate homeostasis, recent studies also implicate them in
bone mineralization and vascular calcification, thereby suggesting patho-physiological rele-
vance. This underscores the need for detailed characterization of their transport mechanism,
physiological role in Pi homeostasis and structure-function relations. To characterize their
transport mechanism three SLC20 clones (Xenopus PiT1, human PiT1, and human PiT2)
were expressed in Xenopus oocytes. Each clone gave robust Na-dependent 32P uptake, but
only Xenopus PiT1 showed sufficient activity for complete kinetic characterization by using
two-electrode voltage clamp and radionuclide uptake. Compared with the well-characterized
electrogenic SLC34 proteins (NaPi-IIa/b) that preferentially cotransport divalent Pi with a
3:1 Na+:Pi stoichiometry, PiT1 was found to have a stoichiometry of 2:1 Na+:Pi and prefers
monovalent Pi, 1 charge was translocated per Pi. Unlike SLC34 proteins, PiT1 transport
activity was less sensitive to acid pH. Significantly, in contrast to type II Na+/Pi cotrans-
porters, the transport inhibitor phosphonoformic acid (PFA) did not inhibit PiT1 or PiT2
activity. This latter finding was used as a tool to identify PiT2 as a potential contributor
to renal Pi uptake in the rat kidney. Here, it was shown that 32P uptake in rat renal brush
border membrane vesicles was incompletely suppressed in the presence of high concentrations
of PFA that would normally fully inactivate the contribution due to the main mediators of
Na+-coupled Pi cotransport (NaPi-IIa, NaPi-IIc). Moreover, PiT2 was localized to the brush
border membrane (BBM) of the proximal tubule epithelia and its abundance, confirmed by
western blot and immunohistochemistry of rat kidney slices, was regulated by dietary Pi.
Taken together these findings define a new role for PiT2 in renal phosphate homeostasis.
Because of its relative insensitivity to changes in tubular pH and its adaptive time course
of down regulation that is intermediate between that of NaPi-IIa and NaPi-IIc, PiT2 may
play a significant role in the physiological response to changes in Pi diet. Finally, structure-
function studies were performed on the Xenopus PiT1 isoform with the aim of identifying
functionally important sites in the protein and establishing the topology in regions exposed
to the extracellular medium. Previous topology studies have identified residues associated
with the retrovirus receptor binding site but the remaining secondary topology is less well-
defined. For the PiT2 isoform the predicted first extracellular loop has been reported to
contain residues critical for substrate interaction and transport function. This region is iden-
tical in the Xenopus PiT1 isoform. Therefore the substituted cysteine accessibility method
(SCAM) was applied to investigate structure-function relationships. Residues important for
the transport function were identified and the accessibility of this region from the extra-
I
cellular medium was confirmed and quantitated in terms of the rate of modification of the
substituted cysteines.
II
Zusammenfassung
PiT1 und PiT2, zwei Vertreter der SLC20 (solute carrier) Familie, welche urspru¨nglich als
retrovirale Rezeptoren identifiziert wurden, transportieren anorganische Phosphat-jonen (Pi)
zusammen mit Na+-jonen durch zellula¨re Plasmamembranen. Zusa¨tzlich zu der vorgeschla-
genen “housekeeping” Funktion in der Phosphathomeostase bringen ku¨rzlich vero¨ffentlichte
Studien PiT1 und PiT2 in einen Zusammenhang mit der Knochenmineralisation und der
vaskula¨ren Kalzifizierung und zeigen dadurch ihre physiologische und pathophysiologische
Relevanz. In dieser Arbeit wurden die Transportmechanismen, die Rolle in der renalen Auss-
cheidung von Pi sowie Struktur-Funktions-Beziehungen der PiT1 /PiT2 Na/Pi-Kotransporter
untersucht.
Um den Transportmechanismus zu charakterisieren wurden drei veschiedene SLC20 Na/Pi-
Kotransporter (Xenopus PiT1, human PiT1 und human PiT2) in Oozyten von Xenopus
laevis exprimiert. Expression jeder der verwendeten Isoformen zeigte Na+-abha¨ngige Auf-
nahme von (32P) Pi, jedoch zeigte nur die Expression von Xenopus PiT1 ausreichende Ak-
tivita¨t, welche fu¨r eine umfassende Charakterisierung unter Verwendung von elektrophysiol-
ogischen Techniken erforderlich ist. Die Ergebnisse dieser Untersuchungen zeigten, dass der
PiT1 vermittelte Na/Pi-cotransport elektrogen ist, dass aber im Gegesatz zu den elektro-
genen SLC34 Na/Pi-Kotransportern (NaPi-IIa/b), welche bevorzugt divalentes Pi mit einer
3 Na+:1:HPO2−4 Sto¨chiometrie kotransportieren, PiT1 monovalentes Pi bevorzugt und der
Transportvorgang eine Sto¨chiometrie von 2 Na+:1H2PO− aufweist. Im Vergleich zu den
SLC34 Proteinen zeigte die Transportaktivita¨t von PiT1 eine geringere pH-Sensitivita¨t, und
im Gegensatz zu Typ II Na+/Pi-Kotransportern, wurden die Transportaktivita¨ten von PiT1
oder PiT2 durch Phosphonoameisensa¨ure (PFA) nicht gehemmt.
Die letztere Erkenntnis wurde als Werkzeug zur Identifizierung von PiT2 als einem poten-
tiellen Mitspieler der renalen Ru¨ckresorption von Pi in der Niere benutzt. Es konnte gezeigt
werden, dass die Aufnhame von 32P in isolierte Membranvesikel der Bu¨rstensaummembran
des proximalen Tubulus der Rattenniere in Gegenwart hoher Konzentrationen von PFA nicht
vollsta¨ndig unterdru¨ckt wurde. Dabei handelte es sich um PFA-Konzentrationen, welche
die beiden Hauptmediatoren der renalen Ru¨ckresorption von Pi (NaPi-IIa bzw. NaPi-IIc)
vollsta¨ndig inaktivieren. Daru¨ber hinaus wurde gezeigt, dass PiT2 an der Bu¨rstensaummembran
des proximalenTubulus lokalisiert ist und dass die Anzahl PiT2 Kotransporter durch in
der Nahrung aufgenommenes Pi reguliert wird. Interessanterweise unterscheidet sich der
zeitliche Verlauf der Regulation von PiT2 von demjenigen der NaPi-IIa und NaPi-IIc Na/Pi-
Kotransporter. Zusammengenommen definieren diese Ergebnisse eine neue Funktion fu¨r PiT2
fu¨r die renale Ru¨ckresorption von Pi und somit auch fu¨r die gesamte Phosphathomeostase
Struktur-Funktions Studien unter Verwendung der Xenopus-PiT1 Isoform wurden mit dem
III
Ziel durchgefu¨hrt, funktionelle Stellen im Protein zu identifizieren, welche fu¨r den Trans-
portvorgang wichtig sind. Dabei wurde ein Modell der Sekunda¨rstruktur verwendet, welches
bei der Aufkla¨rung der Bindungsstelle fu¨r Retroviren verwendet wurde. Um Struktur-Funktions-
Beziehungen zu erarbeiten, wurde die sogenannte “substituted cysteine accessibility” Meth-
ode (SCAM) angewandt. Es wurde hauptsa¨chlich die erste extrazellula¨re Doma¨ne untersucht,
welche bei PiT1 und PiT2 Kotransportern identisch ist. Dabei wurden fu¨r die Transportfunk-
tion wichtige Aminosa¨uren identifiziert und deren Anordnung wurde aufgrund der Kinetik
der Modifikationsreaktion der substituierten Cysteine beschrieben.
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Introduction
1
Chapter 1
Transport across the plasma
membrane.
The plasma membrane defines the physical boundary of the cell and acts as permeation
barrier so that essential differences in the fluid composition between the intracellular and
the extracellular compartments can be established, maintained and regulated throughout the
life of the cell. In all cells the plasma membrane is made up of a 5 nm double layer of
phospholipids, orientated with the hydrophobic chains facing together and the hydrophilic
heads facing the aqueous compartments [1]. Movement of solutes as well as water across the
plasma membrane is mediated by membrane transport proteins. These can be conveniently
classified according to their structure-function properties as pores, channels and carriers (see
fig. 1.1). This classification is largely based on how the solutes access the transmembrane
pathway [1].
1.1 Pores.
Pores provide an aqueous transmembrane passageway that is always open. A pore allows
the passage of approximately 109 particles per second (water, glycerol, small lipids etc.).
Among the large-size pores are the porins found in the outer membranes of gram-negative
bacteria and mitochondria that allow solutes as large as 5 kDa to diffuse passively from the
cytosol into the mitochondria’s intermembrane space. The plasma membranes of many types
of cells have proteins that form channels large enough to allow only water molecules to pass
through, like the aquaporin 1 (AQP1) (see example b in fig. 1.2: the pathway between the two
sides of the membrane is always open). AQP1 belongs to a larger family of aquaporins that
has representatives in organisms as diverse as bacteria, plants, and animals. In mammals,
the various aquaporin isoforms have different tissue distributions, different mechanisms of
1
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regulation, and varying abilities to transport small neutral molecules other than water. In
the lipid bilayer, AQP1 exists as tetramers [2].
Figure 1.1: Representative structures of channels above and transporters below obtained from crystallo-
graphic data [3].
1.2 Ion channels.
Channels specifically allow the selective passage of ions across the membrane. Ion channels
are composed of one or more polypeptide subunits with α helical membrane transmembrane
domains (see example a in fig. 1.2). Channels have several functional components that can
now be related to their structure:
1. gate - determines whether the channel is open or closed
2. sensor - responds to one of several different types of signals: changes in membrane
potential, second messenger systems that act at the cytoplasmic face of the membrane
protein, or ligands like neurohumoral agonists that bind to the extracellular face of the
membrane protein
3. selectivity filter - determines the kind of ions that have access to the channel pore
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4. pore - provides the continuous pathway between the two sides of the membrane so that
ions can flow passively by diffusion until the channel closes.
When the gate is open the two sides of the membrane are in direct communication as shown
in fig. 1.2. Channels can be ligand gated like the nicotinic acetylcholine receptor (nAchR
in fig. 1.1), voltage gated (like Kv1.2 in fig. 1.1), mechanosensitive like the K+ channels
TRAAK (example MscS and MscL in fig. 1.1), etc. Channels are extremely selective for
specific ions (cations or anions) and allow the passage of up to 108 ions per second according
to the prevailing electrochemical gradient; this means that in terms of solute energetics they
are dissipative.
1.3 Carriers.
Carriers show a complex secondary structure involving multiple transmembrane domains
(see example c in fig.1.2). They have been classically viewed as “vectorial” enzymes whose
catalytic cycle involves:
1. relatively selective recognition/binding of the substrates
2. conformational changes in the transporter itself due to binding of the substrates
3. coupling of these conformational changes to physical movement of the ions across the
membrane
Each carrier protein has a specific affinity for binding one or a small number of solutes, and
transporting them across the bilayer. Carriers have a limited speed with which they can cycle
through the various steps. A progressive increase of the solute concentration leads the carrier
to transport solute at maximum rate. In contrast to channels and pores a ideal carrier never
allows direct communication between the two sides of the membrane as shown in fig. 1.2.
Carriers exhibit a wide range of flux rates from 10-50000 substrate molecules · s−1. GAT1
(γ-aminobutyric acid (GABA) transporter 1) for example show a unitary turnover rate of 15
± 2 s−1 (21◦C, −50 mV) [4], the Na+−K+-ATPase show a turnover rate of 500 at 37◦C [5]
and the Cl/Cl exchanger 50000 s−1 at 37◦C [6]. They can be subdivided into three categories:
• uniporters, which move a solute in one direction only
• symporters (or cotransporters), which translocate two or more solutes in the same
direction like cation- or proton-coupled cotransporters
• antiporters (or exchangers), which translocate two or more solutes in opposite directions
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In terms of energetics, membrane transport proteins can function passively or actively.
Like pores and channels, uniporter carriers transport solutes “downhill” according to the
chemical potential difference for the specific substrate across the membrane, like the glucose
transporter GLUT. Due to the fact that they follow the electrochemical gradient they cannot
concentrate a solute in a particular side of the membrane. Symporters and antiporters can
move the substrate “uphill” against its electrochemical gradient using various energy sources
[1, 7, 8]. They can generate a solute gradient, exploiting the electrochemical gradient of
another solute. They can be:
• primary active carriers, that use the energy available from the direct hydrolysis of the
high energetic pyrophosphate bonds like ATP and GTP. These are exemplified by the
exchanger Na+-K+-ATPase or the uniporter H+-ATPase.
• secondary-active carriers, that utilize the energy stored in the electrochemical gradient
of ions like Na+ to move other substrates across the membrane. A typical example is
the Na+ coupled glucose transporter (SGLT1).
Figure 1.2: 3-D structures of (a) potassium channel KcsA [9], (b) water channel Aquaporin-1 (represented
the functional unit) [2] and (c) lactose permease LacY [10]. In the upper part: view from the top of the
membrane, in the lower part: the side view. Note that clear transmembrane pore region is only seen for the
pore and the channel.
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1.4 Channels vs Carriers.
The existence of proteins in the membrane that facilitate the passage of solutes was pos-
tulated in the fifties by Hodgkin and Huxley to explain the Na+ and K+ permeability in
neurons [11]. In 1952 the concept of a cotransporter was introduced: a protein that ex-
ploit the driving force of a substrate to drive another one [12]. The transport of molecules
against their electrochemical gradient was mechanistically explained using an enzyme theory
associated with carrier kinetics developed in the late sixties [13]. With the development of
new investigation techniques, using electrical recordings and radiolabeled flux measurements,
channels and carriers could be distinguished one from the other. The transport rate is usually
many times faster for a channel than for a transporter because it does not require a defined
sequence of energetic interactions between the channel and the transported ions, like occur for
a transporter. This constitutes one of the major functional criteria classically used to distin-
guish channels vs. transporters. With the introduction of high-resolution electrophysiology
techniques, like the patch clamp, this clear division began to blur because the recognition of
channel-like currents in cotransporters.
One example is the glutamate transporter that belongs to the excitatory amino acid trans-
porter (EAATs) family (SLC1) expressed in neurons and glial cells, where they limit the extra-
cellular glutamate concentration. EAATs exhibit an anion channel activity which, although
uncoupled from the glutamate transport mechanisms, is nevertheless gated by glutamate.
The EAAT channel is Cl− selective, and its activation alters synaptic currents more rapidly
than Na+-coupled glutamate transport turnover (10 s−1). In voltage-clamped Xenopus lae-
vis oocytes, in which it is possible to measure ion current and substrate flux simultaneously,
charge-flux ratios may vary from 12 to more than 100 [14].
In contrast, Accardi, Miller, and colleagues showed that ClC-ec1, a membrane protein pre-
dicted by homology to be a Cl− channel, is actually a Cl−/H+ exchanger [15], Cl− flux in one
direction is positively coupled with H+ flux in the opposite direction with a stoichiometry of
1H:2Cl. ClC-ec1 does not have an obvious channel motif, but then neither do homologous
members of the CLC family, which are all thought to be authentic Cl− channels. Channel-like
activity and transporter-type activity can be encounted within the basic structures of most
ion transport proteins.
There are examples of transporters that have been modified either chemically (e.g. toxin
binding) or by point mutation that exhibit channel-like properties. One of them is the Na+-
K+-ATPase pump that can be mutated into a cation channel by palytoxin (PTX), a marine
coral toxin that selectively binds to the Na+-K+-ATPase. It is converted into a non-selective
cation channel that acts to dissipate the transmembrane Na+ and K+ gradients which are
generated by the Na+-K+-ATPase acting in its normal transporter mode [16]. Another exam-
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ple was demonstrated by Dutzler and co-workers who showed that a single mutation returned
ClC-ec1 to a pure chloride selectivity with channel-like properties [17,18].
Chapter 2
Characterization of secondary
active transport proteins.
Characterization of secondary active transport proteins can be undertaken at different levels
that varies from the whole organ and specific cells, down to the protein itself together with its
interacting on associated protein. By integrating information from different levels a complete
characterization can be obtained. In this chapter the characterization will be treated at the
levels that correspond to the three main themes covered in this dissertation: mechanism,
regulation, structure-function. The most convenient approach to study a secondary-active
transport proteins is clone it and over-express it in a simplified system where its characteristics
can be studied without significant contamination from endogenous membrane proteins. A
common expression system for membrane proteins is the oocyte extracted from the Xenopus
laevis frog. RNA coding for the protein of interest is injected in each egg and after a given
time (few hours-few days) it will be translated into the protein by the oocyte ribosomes and
moved to the membrane. One of the main goals of the characterization of a secondary active
transporter is to build a model based on biophysical principles that describes its transport
mechanism.
2.1 Transport mechanism of secondary active carriers.
Important properties that characterize a secondary-active transporter are:
• specificity of substrates and co-substrates,
• Km -apparent affinity - for substrates and co-substrates
• stoichiometry: number of substrate and co-substrates involved in each transport cycle
7
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• binding mechanism: order of substrates and co-substrates interactions with the trans-
porter
• turnover rate: number of transport cycles that a carrier performs per second
• transport cycle: constituted by the partial reactions that correspond to binding / de-
binding of each substrate or co-substrate and the associated conformational changes
that allow the carrier to translocate them across the membrane.
• dependence on pH, membrane voltage, presence of the co-substrates
• inhibitors and their mechanism of interaction: competitive, non-competitive or mixed.
• electrogenicity
A transporter can be electrogenic, it can translocate electrical charges per cycle of transport,
or electroneutral. If the transporter is electrogenic it is possible to investigate the currents
induced by the substrates by electrophysiology using two-electrode voltage clamp or patch
clamp, there one must first establish if the currents directly reflect the transport process.
For electroneutral transporters it is possible to perform assays with radiolabeled substrates
or label the transporter with fluorescent dyes. To show that an interacting molecule is really
transported across the membrane it is necessary to use isotopes such as 32P for the phos-
phate transporters or aminoacids containing 14C for the amino acid transporters or tritium
for proton-coupled transporters. Applying different concentrations of substrates allows the
determination of the apparent affinity by recording the response to the substrate and fitting
the data with model equations to obtain so-called phenomenological parameters. For example
it is possible to fit the data with a Hill equation:
V0 =
Vmax · [S]nH
[S]nH + [KS0.5]nH
(2.1)
where V0 is the response (initial reaction rate for the enzymatic reactions), Vmax is the
maximum predicted response and [S] is the substrate concentration. KS0.5 represents the
substrate concentration at which the response is half maximal. The Hill coefficient, nH,
indicates cooperativity of the substrates: if nH= 1 the dependence on [S] is hyperbolic and
corresponds to the Michaelis-Menten equation; if nH > 1 the dependence on [S] is sigmoidal
and indicates cooperativity of the substrate interaction.
It is important to evaluate the carrier behavior at different pHs modifying the pH of the
media and comparing the values obtained for the Km and the Vmax to understand the inter-
action of protons with the transporter. They can in fact stimulate or inhibit the interaction
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between carrier and substrates or compete with the substrates. In case of multiple substrates
that bind, it is important to define if the binding is an ordered or random process. This is
done by varying the concentration of one substrate vs. the other and see how that influ-
ence the transport. To establish the stoichiometry, it is useful to perform assays with both
substrates and co-substrates radioactive, or, in case of an electrogenic carrier, to perform
two electrode voltage clamp with radioactive tracers, to evaluate the ratio charge/molecule
translocated.
To describe the transport mechanism of a secondary active transporter two models have
been proposed:
• Alternating access model (fig. 2.1)
• Multi-substrate single-file model (fig. 2.2)
The alternating access model considers a carrier like a gated channel, with a pore containing
the binding site for the substrates, and two gates that are alternatively closed or open,
preventing the communication pathway between the two sides of the membrane (see fig.
2.1). When the first gate is open, the first substrates can access to the binding site. This
induces a conformational change that allows the second substrate to bind and so on, until
all the binding sites are fully loaded. The external gate would close, occluding substrates
and binding sites. This closed complex is instable and a second gate would open to release
the substrates and return to the empty state [19, 20]. This model can explain only some of
the carrier-mediated transport properties like coupling stoichiometry or transient currents, in
case of an electrogenic transporter. Newer measurements have also revealed additional classes
of complexities that cannot be explained by straightforward alternating-access models. There
are leakage currents - Na+ fluxes in the absence of substrates [21]. There are major departures
from accepted stoichiometry, so that transport associated currents are several times larger
than the flux of organic substrate [22]. There are quantized current events that exceed by
several orders of magnitude the single-charge events expected from the model [23].
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Figure 2.1: Schematic representation of the alternating access model, adapted from [24]
The multi-substrate single-file model has been proposed as an alternative to address
these issues. Here, the transporter is considered as a channel with all the binding sites “lin-
early” distributed along a pore structure similar to the earlier Hodgkin and Keynes model
for single-file ion movement in a K+ channel [25]. After the substrate enters the transporter
it can move from one site to the other as soon it will be free. This “single-file” substrate
movement proceeds until the exit from the transporter. Each binding site is separated by
an energy barrier that needs to be passed to precede to the next binding site. In this model
the transporter forms a pore that is always open and ready to translocate the substrates in
a defined direction depending on substrate availability (see fig. 2.2). This model has been
tested on GAT1, 5-HTT and SGLT1 and it was qualitatively in agreement with the steady
state data but does not furnished any information about the transport function. The major
limitation of this method is the impossibility, so far, to deal with antiporter or exchanger [20].
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Figure 2.2: Schematic representation of the multi-substrate single-file model. Top: the structure of a
transporter with three binding sites, center: the events that are allowed, bottom: the transporter in presence
of two substrates (figure adapted from [20]).
Both models take into account the influence of the membrane potential on the transport
rate. To understand which model better describes the transporter behavior intensives studies
have been done on the GABA transporter GAT1, the result was in favour of the alternating
access model [26]. These models are useful tools to understand the transport mechanism but
they cannot provide a link between the mechanism with the structure-function aspect of a
transporter.
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2.2 Structure and structure-function studies.
The essential structural and functional elements of proteins, rather than their amino acid
residues, are conserved during evolution. The tertiary structure of a protein describes the
folding of its secondary structural elements and specifies the position of each atoms, including
its side chains, in the protein. To describe structure-function relationships of a protein is
done by identifying functionally important elements in the protein that confer the transport
properties and thus contribute to the ultimate goal of having a 3-D model of the protein that
conveys both structural and functional information [27].
2.2.1 Crystallographic approach to investigate protein structure-function.
The knowledge of the 3D structure of a protein is extremely useful to identify functionally
important sites, like substrate binding sites, voltage or pH sensitive sites, and to acquire infor-
mation about the possible conformational changes involved in the mechanism of the protein.
Obtaining a protein 3D structure is a multi-step process involving extraction, purification,
crystallization of the protein and X-ray diffraction of the crystal. The resolution of the crystals
can vary from 2A˚ to 10A˚. Membrane proteins show a typical structure composed of alternated
hydrophobic and hydrophilic domains stabilized by a phospholipid bilayer, they are insoluble
in aqueous buffers and they can denaturate in organic solvents. Direct consequences of these
properties are the difficulty to extract and purify enough protein to proceed with the crystal-
lization and to stabilize of the protein during the crystallization phase. Another significant
problem in protein structure determination comes from the extreme non-physiological condi-
tions of the crystallization process: high pH, low temperature, complexes with the antibodies
needed to stabilize the protein. All these conditions can lead to structural artefacts. The
knowledge of the crystal structure of a membrane protein can still leave open questions such
as whether the folding revealed in the crystal is the same architecture as in the phospholipid
bilayer and under physiological conditions. Information on the molecular dynamics is missing
and the structure corresponds to only one possible conformation of the protein.
Structure of channels and pores have been the first to be resolved by X-ray diffraction of
the crystals [28–30]. Fortunately also some carrier type membrane proteins have been crys-
tallized and their structure resolved like the Na+/H+ antiporter from E.coli [31] or lactose
permease LacY from E.coli [10] or the glutamate transporter homologous of P.horikshii [32]
or the bacterial homolog Na+/Cl− neurotransmitter transporter [33]. Many of the resolved
crystal structures are from bacteria, expression and purification of mammalian proteins still
present many difficulties and this leads to a lack of knowledge in the structure of mammalian
isoforms. Many protein structures show a two-fold symmetry: the division of the protein
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structure in two structurally similar half that may have evolved from a gene duplication [30].
The 3D structure so far obtained from the X-ray diffraction of the crystal immortalize the
protein in an unique conformation. Ideally to have crystal for every conformational change
of the protein would help to better understand the transport cycle. Crystal studies need to
be integrated with structure-function studies conducted under physiological conditions.
2.2.2 Non-crystallographic approaches to investigate protein structure-
function.
The possibility to study under physiological conditions the functioning of a protein allows
the identification of important sites and link them with the structure where possible. Some
methods have been proposed to investigate structure-function properties of proteins and they
have became extremely useful when applied to membrane proteins that have resisted to the
crystallization or where the crystals have yielded poor resolution.
Biochemical methods
SCAM. The substituted-cysteine accessibility method (SCAM) was first introduced by the
Karlin group to study ion channel lining residues of the acetylcholine receptor channel [34],
and then was extended to other multiple transmembrane segment proteins such as LacY [35],
or AE1 the erythrocyte anion exchanger [36] and the type IIa Na+-Pi cotransporter [27,37].
It is a powerful technique that uses the specificity of sulfhydryl chemistry [38]. Cysteine
residues contain sulfhydryl groups that react with a variety of sulfhydryl-specific reagents.
To evaluate the importance of a specific residue within a protein it is possible to mutate it to
a cysteine. The cys-modification may result in a clear alteration of the transport properties
that can be detected by electrophysiology or tracer-flux techniques. One class of compounds
that can react with the cysteine are the methane-thiosulfonate reagents (MTS) by creating
disulfide bridges (fig. 2.3). There are different MTS reagents with different charges and
volumes. SCAM is based on certain observations. In aqueous media sulfhydryl reagents
react with ionized sulfhydryls about 5·109 times faster than with unionized SH. Thus, if a
sulfhydryl group is in the lipid-accessible surface or in the protein interior, it will not be
reactive, because ionization of SH is suppressed due to the low dielectric constant of the
environment. The sulfhydryl group of a cysteine residue in a membrane embedded channel
or transport protein could be in one of three environments: the water accessible surface, the
lipid-accessible surface, or the protein interior. In the presence of sulfhydryl-specific reagents,
sulfhydryls in the water accessible surface will be covalently modified by the reagents [39].
The presence of this added molecule reveal information about accessibility and is importance
in the functioning of the protein of that residue and the region around it. This new structure
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can further modify the properties of the mutant compared to the wild type.
Figure 2.3: Example of a MTS reagent (MTSET) reacting with a cysteine.
Using the information obtained with cysteine scanning it is possible to study the protein
topology, the presence of a secondary structure element like α helix or β sheet or investigate
a pore or a cavity in the structure. If native cysteines react with the thiol reagent they can
give artefacts or allosteric effects, thus ideally all native cysteine should be removed, with the
risk that the cys-free mutant construct no longer behaves as the wild type. If any non native
Cys reacts with the MTS reagent, it is usually assumed that only the novel one is reacting
and all the information are from that particular site of the protein [34,40].
Thiol cross-linking. This method allows the evaluation of the helix packing of a protein.
It is possible to introduce two novel cysteines in two potential sites of the protein and expose
them to a cross linking reagent that contains two thiol groups that react with the two Cys to
form a disulfide bridge. The crosslinker may alter the properties of the transporter allowing
one to infer the distance between two residues and their mobility. In a reducing environment
the disulfide bridge can break and the function can be restored. Reducing agents can interact
also with native disulfide bridges and break them altering the tertiary structure of the protein.
This method has been used with success to elucidate the helix distances in the structure of
LacY [41].
FRET. Fluorescence Resonance Energy Transfer is a mechanism describing energy transfer
between two chromophores. FRET is a useful tool to quantify molecular dynamics such as
protein-protein interactions and protein conformational changes. To investigate, for example,
the complex formation between two molecules, one of them is labelled with a donor and the
other with an acceptor, and these fluorophore-labelled molecules are mixed. When they are
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dissociated, the donor emission is detected upon the donor excitation. On the other hand,
when the donor and acceptor are in proximity (1-10 nm) due to the interaction of the two
molecules, the acceptor emission is predominantly observed because of the intermolecular
FRET from the donor to the acceptor. For monitoring protein conformational changes, the
target protein is labelled with a donor and an acceptor at two positions. When a twist or bend
of the protein alters the distance or relative orientation of the donor and acceptor, FRET
change is observed. The common FRET pair for biological use is a cyan fluorescent protein
(CFP)-yellow fluorescent protein (YFP) pair, colour variants of green fluorescent protein
(GFP). To study intramolecular interactions like such as protonation and the sugar binding
on Lac Y, it is preferable to use smaller chromophores like DACM (N-(7-dimethylamino-4-
methylcoumarin-3-yl)maleimide) or MIANS (2-(4’-maleimidylanilino)naphthalene-6-sulfonic
acid) organic compound characterized by a multiple-ring system [42]. They in fact interfere
less with the movement of the protein thank to the reduced dimensions and emits fluorescence
thanks to the highly mobile electrons of the ring system.
SDSL. Site-directed spin labelling (SDSL) is a useful technique employed for mapping ele-
ments of secondary structure. The common approach in SDSL is to introduce a novel cysteine
into a protein with all non disulfide bonded cysteines removed by site-directed mutagenesis
and then to modify this unique cysteine with a nitroxide spin label. This introduces at a
specific site within a protein a molecular probe that provides unique spectral signatures in
conventional electron paramagnetic resonance (EPR) experiments. The SDSL method was
extended to site-specific spin labelling of two sites in a protein or peptide (double site-directed
spin labelling, D-SDSL). The distance, and in some cases the relative orientation, between
the two spin labels were determined from analysis of spin-spin. If is already available an
high resolution structure for a given protein it is interesting to determine how this structure
changes under conditions relevant to the function, or to understand the kinetics of structural
changes related to the function [43–45].
2.2.3 In silico approaches.
Although large amounts of protein sequence data are produced by modern large-scale DNA
sequencing efforts, the output of experimentally determined protein structures is not even
comparable due to the high time-consuming and costs of the two main techniques X-ray
crystallography and NMR spectroscopy. The possibility to predict the structure of a protein
starting from the primary sequence becomes an important goal. Protein structure prediction
is made difficult by many factors, the main ones being that the number of possible protein
structures is extremely large, and that the physical basis of protein structural stability is not
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fully understood. Direct simulation of protein folding in atomic detail, via methods such as
molecular dynamics with a suitable energy function, is limited by the number of residues,
due to the high computational cost. In addition: -1- some proteins require stabilization
by additional domains or binding partners to adopt their native structure -2- the tertiary
structure of a native protein may not be readily formed without the aid of additional agents,
for example, chaperone proteins. Other proteins cannot fold properly without modifications
such as glycosylation -3- a particular protein may be able to assume multiple conformations
depending on its chemical environment -4- the biologically active conformation may not be
the most thermodynamically favorable. Due to the increase in computer power, and new
algorithms, much progress is being made however, routine de novo prediction of protein
structures, even for small proteins, is still not achieved.
Comparative protein modelling. This uses previously solved structures as starting
points or templates. This is effective because it appears that although the number of actual
proteins is vast, there is a limited set of tertiary structural motifs to which most proteins
belong. It has been suggested that there are only around 2000 distinct protein folds in
nature, though there are many millions of different proteins. The homology modelling is
based on the reasonable assumption that two homologous proteins will share very similar
structures. Because a protein’s fold is more evolutionarily conserved than its amino acid
sequence, a target sequence can be modelled with reasonable accuracy on a very distantly
related template, provided that the relationship between target and template can be discerned
through sequence alignment. Homology modelling can produce high-quality structural models
when the target and template are closely related, in fact given an amino acid sequence of
an unknown structure and the solved structure of a homologous protein, each residue in the
solved structure is computationally mutated into the corresponding one of the unknown one.
The distance and the dihedral angle restraints for the model are calculated from the alignment
with the template 3D structure. This method has been applied with success for example to
predict the structure of the human facilitative glucose transporter GLUT1 [46], modelled on
the basis of the glycerol-3-phosphate transporter and for the serotonin transporter SERT on
the basis of the LeuT structure [47]. For both transporters the experimental data were in
agreement with the model proposed.
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2.3 Physiological regulation.
Many transporters physically associate with adapter proteins that regulate their subcellu-
lar localization. Additionally, the associated protein may control the direct interaction of
the transport protein with signal transduction complexes that include receptors, second
messenger-producing effector enzymes, and protein kinases. A typical example is the in-
volvement of NHERF-family proteins in the localization and acute regulation of the type II
Na+-Pi cotransporter within apical signaling complexes of renal epithelial cells. Via immuno-
precipitation and immunohistological methods has been demonstrated that many transport
proteins interact, via direct protein-protein association, with a variety of regulatory proteins
that have been generically termed “adapter proteins”. They contain several different types
of highly conserved modular protein-protein interaction domains (for example the src homol-
ogy 2 domains that recognize phosphotyrosine motifs) that allow the associated proteins to
act as molecular bridges between two or more different proteins (see fig. 2.4). These as-
sociated proteins include signaling proteins, membrane transport proteins, and cytoskeletal
elements. They can affect the function of transporters mainly in two ways: - 1 - modulate
the steady-state population at the plasma membrane by affecting trafficking - 2 - concentrate
the transport protein within subdomains of the plasma membrane that are also enriched in
the receptors or other signaling proteins known to acutely regulate the trafficking or activ-
ity of the transport protein [24]. Adapter proteins often contain so-called PDZ interaction
domains [48] (the name derives from three proteins in which the motif was first recognized).
NHERFs comprise a family of PDZ-containing adapter proteins that play important roles in
the regulation of several ion transport proteins [49]. The type II Na+/Pi cotransporter in the
proximal tubule is responsible for most of the reabsorption of phosphate from the glomerular
filtrate. Increases in serum phosphate (due to diet and other factors) elevate PTH levels,
which, in turn, act to decrease the NaPi-II-mediated recovery of filtered phosphate. This
PTH-induced decrease in NaPi-II transport activity involves a rapid decrease in the abun-
dance of NaPi cotransporters in the apical membrane due to acute changes in the steady-state
trafficking of NaPi-II between cell surface and intracellular membrane pools [50]. Is has been
shown that the mechanisms by which PTH triggers the changes in NaPi-II involves NHERFs
as the directly coordinator of the regulation of both Na+/Pi type II cotransporters and PTH
receptors [24].
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Figure 2.4: Scheme of how adapter proteins can regulate the trafficking of ion transport proteins and
the assembly of the signaling complexes that include ion transport proteins, receptors, effector enzymes, and
cytoskeletal proteins. PLC, phospolipase C; GPCR, G protein-coupled receptor (from Dubyak et al. 2004 [24]).
Also phospholipids can interact and influence the membrane protein behavior, the function
of many transporters is directly modulated by the specific binding of phosphatidyl-inositol-
4,5-bisphosphate (PIP2). This binding permits rapid modulation of substrate transport ac-
tivity by highly localized changes in PIP2 synthesis or degradation. The activity of some
transporters increases as the local PIP2 is elevated, whereas others exhibit reduced activity
in the presence of PIP2. Membrane transport proteins positively regulated by PIP2 include
plasma membrane Ca2+-ATPase pumps (PMCA), Na+/Ca2+ exchangers (NCX), Na+/H+
exchangers (NHE) [51]. The ability of PIP2 to act as a positive or negative modulator of
membrane transport proteins underscores its important role in signal transduction at the
cellular level.
Figure 2.5: Scheme of how local changes in phosphatidylinositol-4,5-bisphosphate (PIP2) levels can regulate
the functional characteristics of a nearby ion transport protein (from Dubyak et al. 2004 [24]).
Chapter 3
Transport of inorganic phosphate.
3.1 Phosphate as a physiological solute.
The phosphate ion is a polyatomic ion with empirical formula and PO3−4 and mass of 94.973
g/mol; the central phosphorus atom is surrounded by four identical oxygens in a tetrahedral
arrangement. The phosphate ion carries a negative three formal charge and is the conjugate
base of the hydrogen phosphate ion, HPO2−4 , which is the conjugate base of H2PO
−
4 , the
dihydrogen phosphate ion, which in turn is the conjugate base of H3PO4, phosphoric acid.
In dilute aqueous solution, phosphate exists in four forms. In strongly-basic conditions,
the phosphate ion (PO3−4 ) predominates, whereas in weakly-basic conditions, the hydrogen
phosphate ion HPO2−4 is prevalent. In weakly-acid conditions, the dihydrogen phosphate ion
(H2PO−4 ) is most common. In strongly-acid conditions, aqueous phosphoric acid (H3PO4) is
the main form. The equilibrium between the species in aqueous solution is regulated by the
following reactions:
1. H3PO4 
 H+ + H2PO−4
2. H+ + H2PO−4 
 H+ + HPO2−4
3. HPO2−4 
 H+ + PO3−4
The second reaction predominates under physiological conditions with a pKa = 6.8. In the
extracellular fluid (pH = 7.4) only H2PO−4 and HPO
2−
4 ions are in significant amounts. Their
proportion is 1:4.
Phosphorus plays an important role in many aspects of cellular metabolism like in the syn-
thesis of ATP, source of energy for many cellular reactions, in the synthesis of DNA, RNA
and of 2,3-diphosphoglycerate, which regulates the dissociation of oxygen from haemoglobin.
It is also crucial for intracellular signaling and it is one of the components of the membrane
phospholipids. Inorganic phosphate (Pi) is essential for the formation and mineralization
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of bone. Pi is not only an integral component of the hydroxyapatite crystal, but is also
necessary for the development and the activity of osteogenic cells, which are involved in the
synthesis and calcification of bone extracellular matrix [52]. Changes in phosphorus content,
concentration, or both, modulate the activity of a number of metabolic pathways.
Distribution In the body 80% to 85% of the phosphorus is found in the skeleton (approx-
imately 0.6 kg of elemental phosphorus). A smaller amount of phosphorus (0.1 kg) exists in
the soft tissues, mainly as organic phosphates such as phospholipids, phosphoproteins, nucleic
acids, and nucleotides. An even smaller amount (∼500 mg) is present in the extracellular
fluid as inorganic phosphate. The daily dietary intake of phosphorus is typically 1200 mg,
mostly as inorganic phosphate. Dairy products are the major source. The net absorption
of phosphate by the intestines is approximately 950 mg/day. In the steady state, bone has
relatively small phosphate turnover, about 300 mg/day. The kidneys filter approximately 14
times the total extracellular pool of phosphate per day (∼7000 mg/day) and reabsorb about
6100 mg/day. The net renal excretion of phosphorus is around 800 mg/day, the same as the
net absorption by the GI tract, as shown in fig. 3.1
Figure 3.1: Daily phosphate equilibrium between the major body compartments (from Hruska et al. 2008
[53]).
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Regulation The plasma concentration of total inorganic phosphate depends mainly on of
the equilibrium between bone metabolism, gastrointestinal absorption, and kidney excretion-
reabsorption. About half of total plasma phosphate is in an ionized form, and the rest
either complexed to small solutes (∼40%) or bound to protein (∼15%). Both hypo- and
hyperphosphatemia have severe clinical consequences [53, 54]. The plasma concentration
varies rather widely, between 0.8 and 1.5 mM (2.5-4.5 mg/dl of elemental phosphorus) a
variation of 80% and the filterable phosphate (both the ionized and complexed) varies between
about 0.7 and 1.3 mM. Between 85% and 90% of the circulating phosphate is filterable by the
kidneys. Each day the kidneys filter approximately 7 g of phosphate. As this is more than an
order of magnitude greater than the total extracellular pool of phosphate, this fact suggests
that the kidney must reabsorb most of the phosphate filtered in the glomerulus (fig.3.2).
Figure 3.2: Schematic representation of a kidney vertical section and in detail the scheme of a nephron
(adapted from www.uptodate.com).
Thus kidneys (fig.3.2) are the major players in keeping constant the concentration of the
phosphate in the extracellular fluids and they work under strict physiological regulation. The
net excretion of phosphate is the result of the equilibrium between glomerular filtration and
tubular reabsorption. Under normal physiological conditions ∼80-90% of the phosphate fil-
trate is reabsorbed, mainly in the proximal tubule of juxtamedullary nephrons with a higher
rate in the S1 segments [55]. The reabsorption of phosphate in the proximal tubule is in-
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fluenced by various factors, the three most important are: dietary phosphate, parathyroid
hormone (PTH), vitamin D and fibroblast growth factor-23 (FGF23). A low dietary phos-
phate intake can induce almost a 100% of Pi reuptake from the primary urine, whereas a
high content of Pi in the diet leads to a reduction of proximal tubular reabsorption. PTH
administration induces phosphaturia whereas removal of PTH cause reduction of phosphate
in the urine. The vitamin D effect is opposite to the PTH one, stimulating reabsorption
of Pi [56]. FGF23, in mice leads to hyperphosphaturia owing to a reduction of NaPi-IIa
in the proximal BBM whereas FGF23 deficient mice show hyperphosphatemia [57]. Other
factors that regulate the Pi reabsorption in the proximal tubule are: insulin that enhance
the Pi reuptake and prevent the action of PTH, growth hormone also enhance the reuptake,
glucocorticoids, atrial natriuretic peptide, prostaglandin and also non-hormonal factors like
fasting, plasma calcium acid-base and volume expansion.
Patho-physiology In addition to the physiological regulatory factors there are some patho-
physiological conditions that can alter phosphate homeostasis. Several genetic defects can
cause renal phosphate wasting like X-linked hypophosphatemic rickets, autosomal dominant
hypophosphatemic rickets not associated with hypercalcinuria and hereditary hypophos-
phatemic rickets with hypercalciuria [54, 58]. A form of genetically determined reduction
in renal phosphate handling is detected in Dent’s disease, where mutations in a chloride
channel (CLC5) lead to an apparent Pi transport defect [59]. Disturbance in tubular phos-
phate transport seems to be an early indicator of non specific proximal tubular alteration like
in the diabetes mellitus where the augmented glucose load leads to a phosphaturia induced
by the reduced driving force for the Pi reuptake. The reabsorption of Pi can be reduced also
by a damage of the brush border membrane of the proximal tubule or by the administration
of diuretics like acetazolamide [55,59,60]
3.2 Protein family identified as phosphate transporters.
In principle, two kinds of membrane transport proteins could mediate transport of phosphate
across plasma membrane:
• phosphate selective anion channels
• phosphate transporters
Phosphate channels have been identified in organelles like vacuoles. Movement of phosphate
through slow vacuolar (SV) ion channels and the effects of phosphate on SV currents were
investigated using vacuoles from beetroots of Beta vulgaris [61]. In mammalian skeletal
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muscle sarcoplasmic reticulum, two anion channels , the small conductance (SCl) and big
conductance (BCl) chloride channels, were both found to have a Piconductance. The SCl
channel is a divalent anion channel which can pass HPO−24 . The BCl channel is primarily a
monovalent anion channel [62]. Channels would not be good in creating a Pi gradient across
the membrane compared to the Pi tranporters.
Phosphate cotransporters have been found in all phyla: they translocate Pi using the
electrochemical gradient of either Na+ ions or protons. Phosphate reabsorption at the brush
border membrane of proximal tubule is strictly dependent on the presence of sodium ions,
which indicates that there is no paracellular phosphate pathway [63]. Thus the reuptake
of Pi is mediated by phosphate transporters that use the Na+ electrochemical gradient,
maintained by the Na+/K+-ATPase at the basolateral membrane, as driving force. Two
unrelated families 1 of Na+/Pi cotransporters have been identified as being mainly responsible
for this function: the type II and the type III sodium coupled phosphate cotransporters. They
have been named as SLC34 (NaPi-II) and SLC20 (NaPi-III) according to the Human Gene
Nomenclature Committee Database. So far no detailed information is available about the
identity of proteins that mediate Pi eﬄux at the basolateral membrane.
3.2.1 Type II Na+/Pi cotransporter.
The SLC34 family comprises three members: NaPi-IIa, mainly localized in kidney proximal
tubules and also in osteoclasts and neurons, NaPi-IIb, in small intestine, lung testis, liver,
secreting mammary gland and prostate gland, NaPi-IIc in kidney proximal tubules [66]. Non
mammalian homologs of the SLC34 proteins have been identified in bacteria (Vibrio cholera),
amphibians (Xenopus laevis), invertebrates (Caenorhabditis elegans), and fish (zebrafish or
flounder). That indicates an early evolutionary appearance of the type II Na+/Pi cotrans-
porters [66].
NaPi-IIa.
This was identified by functional expression cloning using Xenopus laevis oocytes from a
rat and human kidney cDNA library. The major site of expression is the renal proximal
tubule and here, this protein (80-90 kDa) is localized in microvilli that constitute the brush
border membrane. Under normal physiological conditions, the abundance of NaPi-IIa is
1Type I Na+/Pi cotransporter. A gene product from the SLC17 family was identified as Na
+/Pi
cotransporter, NaPi type I, in a study where it has been expressed in Xenopus oocytes and was founded in
brush border membrane of proximal tubules [64]. It has been shown that it is not involved in phosphate
reuptake but in organic anion transport [65].
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highest in S1 proximal tubular segments of juxtamedullary nephrons [67]. When the NaPi-
IIa gene is knocked out the mice show a reduction of 70% in the Pi reuptake [59,68]. Na+/Pi
cotransport by NaPi-IIa is electrogenic, involving the inward transfer of one net positive
charge per transport cycle. Divalent phosphate is the preferred species and is transported
together with three Na+ ions [69]. The substrates (three Na+ ions and one HPO2−4 ion) bind
in an ordered manner: 2Na+/Pi/Na+ (see fig. 3.3) [70]. Typical apparent substrate affinities
are: KmP i ∼0.1 mM; Km Na ∼50 mM. In the absence of Pi, the transporter operates in
a uniport mode, whereby Na+ ions leak according to the electrochemical gradient with a
probable stoichiometry of 1 Na+ ion [71]. Protons interact with the empty carrier and the
final Na+ binding steps. Higher transport rates are observed at more basic external pH [27].
The trasnporter show high sensitivity to phosphonoformic acid (PFA) [72].
NaPi-IIb.
NaPi II-b was identified based on EST clones derived from lung tissue [73]. Expression of
NaPi-IIb mRNA has been detected in a number of tissues such as small intestine, lung,
mammary glands, testis, and liver [74]. By immunofluorescence, NaPi-IIb was localized
in brush border membranes of enterocytes, in the apical pole of alveolar type II cells as
well as in apical membranes of mammary secretory cells [66, 73]. On Western blots, fully
glycosylated NaPi-IIb is observed as a band of approximately 108 kDa [66] whereas in weaning
animals NaPi-IIb was reported to be only partially glycosylated [75]. At the primary sequence
level NaPi-IIb differs from NaPi-IIa mainly in the C-terminus, which is rich in cys residues
and longer by approximately 50 amino acids for the NaPi-IIb. Na+/Pi-cotransport is also
electrogenic with a stoichiometry of 3Na:1Pi and with KmP i ∼50 µM and Km Na ∼40
mM. Dependence on pH is moderate, slightly higher cotransport is observed at more acidic
pH [73]. NaPi-IIb is involved in transcellular flux of phosphate in the small intestine [73,76].
The most prominent regulators of NaPi-llb in small intestine are 1,25-(OH)2-vitaminD3 and
low-phosphate diet. Up-regulation of NaPi-IIb induced by these factors is manifested by an
increase of the protein abundance and appears, in adults, to be non-transcriptional [76,77].
NaPi-IIc.
The NaPi-IIc cotransporter was identified based on its homology with the NaPi-IIa cotrans-
porter [78]. The NaPi-IIc transporter has a high affinity for Pi (KmP i ∼70 µM; Km Na ∼50
mM). It is highly pH dependent and exhibits higher transport at more alkaline pH [78, 79],
is electroneutral and exhibits a 2:1 stoichiometry. In rodents NaPi-IIc is localized only in
the apical membranes of the renal proximal tubule - S1 segment- [80, 81]. The relative
abundance of NaPi-IIc protein is significantly greater in the kidney of weaning rodents than
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adult animals, which suggests that the NaPi-IIc transporter is a growth-related renal NaPi
transporter [78]. The key regulators of NaPi-IIc expression are dietary Pi intake, PTH and
FGF23 [78,81]
Figure 3.3: Proposed transport mechanism scheme for SLC34 proteins, numbers indicate conformational
states of the protein. Light grey indicates transitions for intracellularly facing conformational changes that
are uncharacterized (from Virkki et al. 2007 [82]).
Structural aspects of type II Na+/Pi-cotransporters show similarity between the isoforms.
As predicted from structure-function studies [27], each type II Na+/Pi-cotransporter protein
most likely has eight transmembrane domains (see fig. 3.4). Both N- and C-termini are
located in the cytoplasm and all the isoform present multiple N-glycosylation sites in a large
extracellular loop. Furthermore, two short loops (one extracellular and one intracellular) have
been postulated to be important functional regions for the transport pathway (see blue circles
on fig. 3.4)[10, 24]. This model is based on data obtained studying NaPi-IIa and appears to
be valid for the other family members as well, since in all members, the transmembranous
regions are over 80% identical and exhibit the same hydropathy profile [10]. The largest
dissimilarities are found in the N- and C-termini and in the large extracellular loop. Based
on results obtained with tandem constructs of NaPi-IIa, it is assumed that the monomeric
form is sufficient for full type II-mediated Na+/Pi cotransport [66]. There is only one known
inhibitor of the type II of Na+/Pi cotransporter: phosphonoformic acid (PFA) [71,72].
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Figure 3.4: NaPiIIa proposed topology [82]. In blue the re-entrant loops.
3.2.2 Type III Na+/Pi cotransporter: PiT1&2.
The SLC20 family is composed of two members: PiT1 and PiT2. These two proteins were
identified as Na+/Pi cotransporters about 15 years ago; before then they were studied in
the context of their function as surface receptor for Gibbon Ape Leukemia Virus (Galvr-1:
PiT1) and Amphothophic Leukemia Virus (Ram-1: PiT2). One of the most important issues
in virology is the identification of cell surface receptors that act as portals of virus entry
into animal cells. These receptors were first characterized not as molecules, but as genetic
determinants of pseudotype or vector entry [83]. The determination of receptor expression
patterns, and elucidation of the effects of infection on the normal functions of these molecules
are critical investigation points, especially in the case of retroviruses because cells can become
chronically infected, leading to receptor down-modulation and subsequent derangements in
cellular functions.
Several retroviral receptor cDNAs have been isolated like those that mediate infections of
gibbon ape leukemia virus (GALV) and of mouse amphotropic retrovirus, Glvr-1 and Ram-1,
respectively [84–86]. They are distinct proteins with putative multiple hydrophobic trans-
membrane domains. They share about 60% overall sequence identity and they show about
25% identity with a putative phosphate permease of Neurospora crassa [85–88]. These data
have suggested that Glvr-1 and Ram-1 might be transporters. The transporter activities of
Glvr-1 and Ram-1 have been investigated by a systematic approach that involved expression
of these proteins in Xenopus laevis oocytes and measurement of transmembrane currents
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during exposure of the oocytes to different salts and nutrients and by 32P uptake [89, 90].
Results have been confirmed by expression in mammalian cells and measurement of 32P up-
take. These studies concluded that Glvr-1 and Ram-1 are Na+/Pi symporters characterized
by phosphate transport rates affected both by retroviral infection and by changes in extracel-
lular phosphate concentrations. These transporters are electrogenic and mediate net cation
influx [89]. PiT-1- and PiT-2-related proteins are present in all phyla (fig.3.5)
Figure 3.5: Phylogenetic tree of SLC20 cotransporter families. Amino acid sequences were aligned
using ClustalW. GenBank accession numbers are listed in parenthesis. The following sequences were
used: human PiT-1 (NM 005415), mouse PiT1 (AAB31458), rat PiT1 (NM 031148), X. laevis PiT-1
(AAH59957), Danio rerio PiT-1 (NM 213179), mouse PiT-2 (NM 011394), rat PiT-2 (NM 017223), hu-
man PiT-2 (NM 006749), X. laevis PiT-2 (BC084098), Arabidopsis thaliana Pht2;1 (NM 113565), Med-
icago truncatula Pht2;1 (AAN46087), Plasmodium falciparum PfPiT (AJ580003), Neurospora crassa Pho-4
(XM 954396), Escherichia coli PitA (NC 002655), and E. coli PitB (NC 000913) from Virkki et al. 2007 [82].
In prokaryotes and in plants, Pi transport is coupled to the H+ gradient [91–93], whereas
in animals and fungi, the driving cation is Na+ [94–96]. In the bacterium Bacillus subtilis,
the related protein CysP mediates H+/SO2−4 cotransport [97], but so far no other PiT family
member has been shown to transport SO2−4 .
3.2.3.1 Tissue distribution and proposed physiological roles.
Levels of virus receptor expression in different tissues influence the course of retroviral infec-
tion and thus the gravity of the consequent disease. The expression pattern is an important
parameter for gene transduction studies, especially in the case of gene therapy. RNAs of
both PiT1 and PiT2 were detected in mouse, rat and human tissues: kidney, heart, brain,
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placenta, lung, liver, skeletal muscle, pancreas, spleen, thymus, prostate, testis, ovary, small
intestine, colon, and peripheral blood leukocytes (see fig. ??) [84, 88, 89, 98–100]. The ex-
pression patterns vary for each protein: for example in the bone marrow, which contains
little PiT2 RNA but abundant PiT1 RNA, or in the heart, where the proportionS are oppo-
site [89, 101]. The relevance of inorganic phosphate for the formation and mineralization of
bone prompted a detailed investigation of the Pi transporters involved in the development
and activity of osteogenic cells that are involved in the synthesis and calcification of the bone
extracellular matrix. The presence of PiT1 mRNA has been show in osteoblast-like cells like
in human osteosarcoma-derived SaOS-2 [52] or MC3T3 [102] PyMS and calvaria primary cul-
tured cells from new born and adults rats [101]. However it has been shown that the amount
of RNA did not correlate with either the retrovirus infectibility [98] or probably with the
amount of protein expressed at the plasmamembrane. At the protein level the expression has
been documented in liver (PiT1 and 2) [103] and in the kidney (PiT2) [104], mouse tissues
kidney, heart, thymus, muscle and brain (PiT1) [105], in crude membrane preparations from
OK cells and umbilical cord endothelial cells from human, rat, rabbit, hamster and mouse
(PiT1) [105].
Figure 3.6: Expression of human SLC20A1 and SLC20A2 transporter mRNAs in various tissues. Values are
from Nishimura and Naito 2008, normalized to the highest expression level (placenta-SLC20A2: 0.96) [106].
This broad tissue distribution suggested a possible role as phosphate housekeeping but
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recent studies see PiT proteins involved in various physiological and pathophysiological pro-
cesses. For example, PiT-mediated Pi transport appears important in bone mineraliza-
tion [101, 107–111]. It has been shown that in cultured bone-derived cells Pi transport and
PiT mRNA levels are regulated by many factors like Pi, epinephrine, platelet-derived growth
factor (PDGF), insulin-like growth factor (IGF-1), and basic fibroblast growth factor (bFGF)
in osteoblast-like cells [101,112–114]. In addition to playing a role in normal calcification, PiT
proteins were recently implicated in pathological processes, such as calcification of vascular
tissue induced by hyperphosphatemia [115,116].
Regulation of PiT function has also been shown for extra-skeletal cells and tissues like in hu-
man embryonic kidney cells (HEK-293) where PiT1-mediated Pi transport is regulated by Pi
levels and PTH [117]. In rat parathyroid glands, PiT-1 mRNA levels are regulated by plasma
vitamin D and Pi levels [99]. At the protein level only limited data are available regarding the
tissue and subcellular distribution of PiT-1 and PiT-2. In osteoclasts and macrophages has
been shown that transfected protein localizes to the basolateral membrane [118] indicating
an involvement of PiT1 in Pi transport in bone-resorbing osteoclasts. PiT proteins may also
play a role in Pi transport in the distal segments of the kidney [119]: both PiT-1 and PiT-2
mRNAs are present in immortalized mouse distal convoluted tubule (MDCT) cells and the
pH dependence of Pi transport is consistent with PiT-mediated transport. In the liver, PiT-1
and PiT-2 localize to the basolateral membrane in hepatocytes [103], whereas in airway ep-
ithelial cells PiT2 is expressed both apically and basolaterally [120].
Finally, it was recently reported that the malaria parasite Plasmodium falciparum expresses
a homologous PiT protein (Pf PiT) in its plasma membrane and that is critical for supply-
ing Pi to the parasite into the erytrocyte. PfPiT-mediated Pi transport is energized by the
Na+ gradient and, because infection causes a gradual increase in intracellular Na+, there is
adequate driving force for Pi uptake via PfPiT [121].
3.2.3.2 Transport mechanism of PiT1 & 2.
Transport mechanism Very limited characterization of the transport kinetics of either
PiT1 or PiT2 has been reported [89, 100, 101, 119, 122, 123]. In oocytes expressing rat PiT1
or human PiT2 the concentration dependence of phosphate uptake followed as expected
for a solute carrier a Michaelis-Menten kinetics: for PiT1 the Pi apparent affinity (Km)
was 24.1±5.5 µM, and for PiT2 25.3±6.0 µM; in transfected fibroblasts the values were:
70 µM, KmPi for PiT1, and 200 µM for PiT2 [89]. For PiT2 has been reported also a
KmNa of 36.3±19 mM and a Hill coefficient of 1.12 indicating weak cooperativity of Na+
interaction [100]. Kinetic analysis have been investigated in parathyroid glands: Xenopus
oocytes have been injected with rat PiT1 or parathyroid poly(A)+RNA showed that the
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KmPi are (89±13) and (123±59) µM, respectively. The kinetic properties of Pi transport
in Xenopus oocytes expressing rat PiT1 and rat parathyroid glands was not significantly
different (89±13) and (140±20) µM, respectively [99]. In PyMS osteoblast-like cells KmPi
for PiT1 has been evaluated 109±12 µM [101]. For human PiT1 expressed in Xenopus oocytes
a KmPi of 322.5±124.5 µM was determined, while for PiT2 KmPi was 163.5±39.8 µM and
the Hill coefficient was n=2 indicating a cooperative substrate binding [122].
Bøttger and coworkers published that PiT1 and PiT2 sustain Na+/Pi transport function at
various pH values without significant modification of the 32P uptake [122], whereas Olah and
coworkers discovered an increase of 32P uptake in MDTF cell expressing PiT1 at pH 6.5 and
7.5 [90]. Several groups have consistently reported that PiT1 and 2 show reduced activity at
alkaline pH [89,90,100].
The possibility of other substrates interacting with PiTs has been investigated by Bøttger et
al. [122] but without significant findings.
The relative large variations in kinetic parameters reported in the literature for PiT1 and
PiT2 is more than what would be expected for heterologous expression and may reflect the
effect of low membrane expression of the specific transporter. For example, although the
data reported by Kavanaugh et al. (see fig. 3.7) show a typical Pi induced inward current,
the magnitude of this current and uptake are significantly small compared to data published
for SLC34 proteins.
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Figure 3.7: Upper panel: two electrode voltage recording of oocytes injected with PiT1 mRNA (left) or H20
(right). The inward current evoked in the cells expressing PiT1 by application of 100 pM phosphate (solid
bar) is dependent on sodium (hollow bar). No Pi-dependent currents were seen in water-injected oocytes
(right). Voltage-clamp recordings were performed with a holding potential of -60 mV. Lower panel: 32P
uptake in presence or absence of sodium in Xenopus oocytes injected with PiT1 or PiT2 mRNA. Oocytes
were incubated in recording solution containing 32P for 60 min followed by lysis and scintillation spectroscopy.
In the last part of the figure is shown the concentration-dependence of 32P uptake (modified from Kavanaugh
et al. 1994 [89].
3.2.3.3 Structure-function.
Structure-function. A search of the ProDom database [124] identified several domains
within these proteins (see fig. 3.8). They include domains specific for the mammalian iso-
forms of PiT1 and PiT2, like the N- and C-terminal extremities and a large central region,
and domains that are in common with non mammalian isoforms. These homology domains
are called PD1131 and PD7717 in the ProDom database (blue and red colour respectively in
fig. 3.8). Domain PD1131 is found in prokaryotes, fungi, yeasts, and plants. Such duplicated
sequences probably have similar but inverted topologies. PD1131 homology defines the PiT
family of proteins according to a classification proposed by the Transport Commission [125];
the PiT family is also called the Pho-4 family (SwissProt). This family currently includes 37
members and most of them, including mammalian PiT1 and PiT2, PD1131 are duplicated
so that proteins contain amino- and carboxy-terminal copies of PD1131. Alignments of the
68 PD1131 homology domains stored in the ProDom database revealed four blocks of highly
conserved amino acids [126]. They appear adjacent to predicted transmembrane domains and
that conservation among distant species suggests that these regions may be important for
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transporter function. Experimental investigations confirmed the predicted topological organi-
zation of human PiT2: 12 putative transmembrane domains are hypothesized, the asparagine
81 is glycosylated and that locate the first predicted loop in an extracelluar position. Tags
inserted at the NH2 and COOH termini are accessible from the external side, indicating that
both termini are extracellular [126] and the intracellular localization of the large loop 7 was
confirmed using an antibody raised against it [112]. Similar topologies have been suggested
for the malaria parasite transporter PfPiT [121] and for the related H+/Pi transporter from
the plant Arabidopsis [91].
It has been shown that PiT2 retains its retroviral receptor function after deletion of loop
7 as well as transmembrane domains 6-7. Bøettger and co-workers did not investigate the
transport function of their truncated protein, and thus it is unknown whether the large loop
is essential for substrate transport [127]. The ability of a retrovirus to infect cells via its
receptor has been used extensively to investigate which amino acids are crucial for infection
with different viruses and thus also serves as a tool for probing the secondary structure of PiTs.
Most of the attention has been directed towards loop 8. This shows large sequence variability
between different species, and it appears to play a role in determining virus binding [128–130].
Only a few features of PiT topology have been experimentally confirmed, such as the location
of the termini and loops 2 and 7 [126]. More experiments are necessary to establish a definitive
membrane topology for PiT1 and PiT2.
Figure 3.8: Topology proposed by Salau¨n et al. 2001 for human PiT2 . Blue segments are the N-PD1131
and C-PD1131 homology domains, in which numbers in green circles indicate the conserved amino acid blocks.
The red segment is PD7717. As the orientation of loop 6 is still unknown, this segment appears as a striped
line (fig. adapted from Salau¨n [126]).
3.2.3.4 Open questions.
There were many questions that need further investigations such as:
• transport mechanism: pH dependence, binding order, potential substrates and co-
substrates, phosphate preferred species or potential inhibitors of PiT.
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• structure function: the topology of PiT required experimental validation and identifi-
cation of the residues involved in the substrate binding-site.
• regulation and localization: the localization (e.g. apical or basolateral in epithelia) of
PiT transporters in different organs need to be investigated, to better understand their
physiological role, and study which physiological factors regulate their expression levels.
Part II
Projects and Results
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Chapter 4
PiT localisation and regulation.
The Na+-Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical
membrane of rat renal proximal tubules and regulated by dietary Pi
[Am J Physiol Renal Physiol, 2008, 296,F691-699
Silvia Ravera, Ricardo Villa-Bellosta, Victor Sorribas, Gerti Stange, Moshe Levi, Heini
Murer, Jurg Biber, and Ian C. Forster
Submitted 19 October 2008; accepted in final form 8 December 2008
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Chapter 5
PiT transport mechanism
Deciphering PiT transport kinetics and substrate specificity
using electrophysiology and flux measurements.
[Am J Physiol Cell Physiol, 2007, 293,C606C620]
Silvia Ravera, Leila V. Virkki, Heini Murer, and Ian C. Forster
Institute of Physiology and Center for Integrative Human Physiology,
University of Zurich, Zurich, Switzerland
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Chapter 6
PiT structure-function studies.
6.1 Structure-function investigation of the first predicted ex-
tracellular loop of XlPiT1.
6.1.1 Aim of the study.
The main topological information about PiT has been published by Salau¨n et al. [126] and
a topology of 12 transmembrane domains was hypothesized. In 2005 Bøttger and co-workers
investigated the importance of some charged residues in PiT2 [131]. These residues are
highly conserved, also in XlPiT1. Some of them like the Glu-68 and the Asp-76 resulted
important for the transporter activity. Using a topological model of XlPiT1 we verify the
surface accessibility of the protein according to the model starting from the first predicted
loop. This loop contains the corresponding residues investigated by Bøettger and colleagues,
respectively Glu-87 and Asp-95. Using the the Substitute Cysteine Accessibility Method
(SCAM) we specifically wanted to verify the extracellular location of the loop, define its
boundaries, and study the structure-function relationships of this region.
6.1.2 Materials and methods.
Mutated proteins. Mutations were introduced following the Quickchange Site-Directed
Mutagenesis Kit manual (Stratagene Inc.). In brief, 15 ng of the plasmid containing the
Xenopus PiT1 cDNA cloned into KSM vector [132] were amplified with 2.5 U PfuUltra
(Strategene Inc.) DNA polymerase in the presence of 250 nM of primers. PCR amplification
was performed with 25 cycles of 95 ◦C(30 s), 55 ◦C (1 min), and 72 ◦C (12 min). Next, 10 U
of DpnI were added directly to the amplification reaction and the sample was incubated for
1 h at 37 ◦C to digest the parental, methylated DNA. Top10 Ultracompetent cells (Invitro-
gen) were transformed with 1 µl reaction mixture and plated on LB-ampicillin plates. The
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sequence was verified by sequencing (Microsynth). The plasmids were linearized by NotI and
used as a template for the synthesis of capped cRNA by mMESSAGE mMACHINE T3 kit
(Ambion) [133]. Stage V–VI defolliculated oocytes from Xenopus laevis frogs were isolated
and maintained as described previously [70]. Oocytes were injected with 50 nl of cRNA (50
ng). Control oocytes were not injected. Oocytes were incubated at 16 ◦C in modified Barth’s
solution.
Solutions. All standard chemicals and reagents were obtained from either Sigma Chemical
Co. or Fluka AG. The MTS reagents, MTSET, [2-(trimethylammonium)ethyl]methanethio-
sulfonate was obtained form Toronto Research Biochemicals. The solution compositions
(mM) were as follows. (a) Oocyte incubation (modified Barth’s solution in mM): 88 NaCl, 1
KC1, 0.41 CaCl2, 0.82 MgSO4, 2.5 NaHCO3, 2 Ca(NO3)2, and 7.5 HEPES, pH 7.4, adjusted
with Tris. The solution was supplemented with 5 mg/l doxycycline and 5mg/l gentamicin. (b)
Control superfusate (ND100, in mM): 100 NaCl, 2 KCl, 1.8 CaCl2, 1MgCl2, and 5 HEPES,
titrated to pH 7.4 with Tris. (c) Stop solution (ND0): as for ND100, but with choline chloride
replacing NaCl to maintain the same osmolarity. Solutions were titrated with HCl and Tris
to pH 7.4. (d) Substrate test solutions: inorganic phosphate (Pi) was added to ND100 from
a K2HPO4/KH2PO4 stock preadjusted to pH 7.4.
Radiotracer Uptake. For each mutant two groups of oocytes (8–10 oocytes/ group) were
analyzed. The first group was incubated for 5 minutes in ND100 with 1mM MTSET added,
then washed in ND100 for 3 minutes. After aspiration of this solution, we added 100 µl
uptake solution containing 32P 10 µCi/ml. The second group of oocytes was preincubated
in ND100 for 3 minutes and then exposed to the 32P solution. The uptake was allowed
to proceed for 15 min before it was stopped by washing the oocytes four times with 3 ml
ice-cold ND0 solution containing 0.5 mM cold Pi. Uptake of 32P alone was carried out by
using ND100 solution and 1 mM cold Pi, to which 32P (specific activity 10–20 µCi/ml Pi)
was added. After washing, oocytes were placed individually in a scintillation vial and lysed
in 250 µl 20% SDS. 32P activities of individual oocytes were counted by using a Packard
Tri-Carb 2900TR scintillation counter.
Electrophysiology. Standard two-electrode voltage clamp hardware (GeneClamp, Model
500 - Molecular Devices) was used as previously described [132] Clamp hardware was con-
trolled and data were acquired by using pClamp 8 software (Molecular Devices), which also
controlled valves for solution exchange. At the start of each experiment, the oocyte was
clamped to a holding potential of -50 mV and was superfused with ND100 solution. To
measure Pi-induced currents (IPi), the superfusate was switched to one containing Pi and
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the change in the holding current was monitored. When the current had reached a steady
state, the perfusate was switched back and washout of Pi was monitored by observing the
return of holding current to baseline. To measure the MTSET-induced current inhibition,
the superfusate was switched to one containing 1mM MTSET for 3 minutes and then the
oocyte was washed for 2 minutes in ND100. To control the reduction in phosphate-induced
current 1mM Pi was applied again. If a mutant showed reduction in Pi-induced current or in
32P uptake to evaluate the rate of the interaction between protein and MTSET, the current
was continuously measured alternating the superfusate: 30 sec 1mM Pi, 1 min ND100, 1 min
MTSET, 1 min ND100, until the current induced by Pi reached zero or a steady state value.
Data were fitted with an exponential decay equation (eqn.6.1) and an apparent reaction rate
was extracted and used to compare the mutants (eqn.6.2).
I(t) = Imax · e−Kt + I0 (6.1)
K = K∗ · [MTSET ] (6.2)
where K is a rate constant that when corrected with the value of the MTSET concentration
used in the reaction will give K*, the apparent second-order rate constant. It is the measured
current, Imax is is the maximum current attainable and I0 a variable offset.
Measurement of apparent Pi and Na+ affinities. The oocyte was voltage clamped at
-50 mV, and the holding current was continuously recorded. To measure IPi , the superfusate
was switched to one containing Pi and change in the holding current was monitored. When
the current had reached a steady state, the superfusate was switched back and washout of Pi
was monitored by observing the return of holding current to baseline. When IPi was recorded
for another Na+concentration or pH, the holding current was first allowed to stabilize at the
new reference solution before being switched to one containing Pi. To determine the apparent
affinity constant for Pi (KPi0.5 ), IPi was measured by using different Pi concentrations while
keeping the Na+ concentration constant. Estimates of KPi0.5 was obtained by fitting data with
the modified Hill equation (eq.6.3)
IPi =
ImaxPi · [S]nH
[S]nH +KnH0.5
+ IOFF (6.3)
where ImaxPi is the maximum current attainable, IOFF is a variable offset, [S] is the variable
substrate concentration, and nH is the Hill coefficient. The voltage dependence of IPi was
measured by applying potentials from -160 to -40 mV and subtracting the current records
for the same potential in the presence and absence of Pi, as described previously (17, 55).
To account for the differences in expression levels between individual oocytes, data obtained
from each oocyte were normalized to IPi recorded at -100 mV with 100 mM Na
+ and 1mM
Pi in the bath at pH 7.4 before the data was fitted with eq.6.3.
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6.1.3 Preliminary results.
Topology model.
Topology prediction from the primary sequence. We used algorithms (Prediction
of Transmembrane Regions and Orientation - TMpred [134]) to analyze the hydrophobicity
of XlPiT1 and hypothesize the secondary structure elements present in the protein to build
a topology model of XlPiT1.
Figure 6.1: Hydropathy plot of XlPiT1 obtained with TMpred (http://www.ch.embnet.org/cgi-
bin/TMPRED).
From the TMpred prediction we can hypothesize 10-12 transmembrane domains (see an
example in tab.6.1). Some of the possible predictions are in contrast with experimental data
published by in 2001 from Salau¨n et al. [126] for PiT2 where they tagged both -NH2 and
-COOH terminus and they showed that they are extracellular. From the PROSITE motif
search four potential N-glycosylation sites have been identified, one of them, the Arg-100, is
the corresponding residue in PiT2 of Arg-81 that has been shown by Salau¨n et al. [126] to
be glycosylated.
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from to length score orientation
1 25 41 (17) 2645 o-i
2 57 81 (25) 948 i-o
3 105 126 (22) 1461 o-i
4 129 151 (23) 1038 i-o
5 166 184 (19) 2243 o-i
6 205 227 (23) 1658 i-o
7 235 255 (21) 3343 o-i
8 519 535 (17) 1553 i-o
9 568 584 (17) 2511 o-i
10 608 626 (19) 957 i-o
11 655 683 (29) 2029 o-i
Table 6.1: Prediction of XlPiT1 transmembrane domains.
(a) (b)
Figure 6.2: Proposed topology for XlPiT1; (a) XlPiT1 proposed topology, the first predicted loop is boxed
and shown in detail in (b). Coloured residues correspond to the coloured bars in the fig. 6.3.
Preparation of mutants.
Nineteen mutants were prepared by substituting one by one the native residues of the first
predicted loop of the wild type XlPiT1 with a cysteine from Lys-84 to Leu-105 (see panel b
in fig. 6.5a) .
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32P screening of the mutants.
All the mutants were expressed in Xenopus oocytes and screened by 32P uptake for functional
expression with or without 5 min pre-incubation with MTSET 1 mM. Seven mutants showed
a reduced 32P uptake after the pre-incubation of MTSET 1 mM while two mutants showed
an increase in 32P uptake. The oocytes expressing the mutant D95C showed a 32P uptake
comparable with the non-injected oocytes, from these data it is not possible to determine if
the mutant is non-functional or not expressed. These data are in agreement with the findings
of Bøettger et al. [131].
Figure 6.3: 32P screening of the mutants. Oocytes exposed to 0.1 mM Pi (coloured bars); oocytes exposed
to 0.1 mM Pi pre-incubated with 1 mM MTSET in ND100 (open bars). Light blue bar: mutants that were
not modified after the incubation with MTSET; yellow: mutants that show reduced uptake after exposure;
orange: mutants that show an increased 32P uptake; green: mutant D95C that shows a strongly reduced
uptake compared with the wild type.
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Electrophysiological screening of mutants. All mutants were expressed in Xenopus
oocytes and tested by two-electrode voltage clamp to compare their electrogenicity, voltage
dependence, substrate and co-substrate apparent affinity with the wild type. We started
with the mutant that showed a reduced 32P uptake after the pre-incubation with MTSET.
All the mutants were electrogenic. D95C that showed a low 32P uptake also gave a small
Pi-induced current, dependent on the membrane voltage. We have not compared expression
levels, thus the reduced Pi-induced current and the reduced 32P uptake may result from low
expression levels or altered kinetics. We tested the mutants with or without pre-incubation
with MTSET and we verified that the modification induced by MTSET was reversible using a
DTT (dithiothreitol) solution 1mM that breaks the disulfide bridge and restores the sulfhydryl
group (data not shown). Fig. 6.4 details the electrophysiological characterization of mutant
S86C and compares its Pi- dependence and the phenomenological parameters ImaxPi , K
Pi
0.5
(the apparent affinity for Pi) with the wild type whereas voltage dependence of ImaxPi was
unchanged, KPi0.5 was significantly altered by the Cys substitution. This suggests that this
site is a critical determinant of Pi interaction with the protein.
Figure 6.4: Data obtained by two-electrode voltage clamp on oocytes expressing XlPiT1 and the mutant
S86C.
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Determining the rate of Cys-modification.
To quantitate the rate of Cys-modification by MTSET for each mutant, we exposed the
oocytes expressing the mutants to a low dose of thiol reagent and we quantitated the pro-
gressive reduction in current induced by Pi until a plateau was reached. We fitted the data
with an exponential equation (eqn.6.1). The constant K obtained was corrected using the
concentration of MTEST employed in the reaction, to gave K* the apparent second order rate
constant, used to compare the mutants. A high K* can be interpreted as high accessibility
of the residue from the external solution.
(a) (b)
Figure 6.5: Example of determination of Cys-modification reaction rate: a: recording of Pi-induced current
after consecutive applications of MTSET; b: normalized value of current-induced by phosphate after exposure
to MTSET for exposition for 1 min. The values have been fitted with the eqn.6.1.
Figure 6.6: K* values calculated for the mutants that showed reduced 32P uptake in presence of MTSET
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Summary The data obtained so far allow us to locate this region extracellularly and to
hypothesize its role in the transport function due to reduced 32P uptake and Pi-induced
current when this region is buried by MTS reagents. So far we cannot determine if it is
involved directly in the coordination of the substrates or if it is involved in the conformational
changes that occur during the transport cycle.
Chapter 7
Other Publications
Temperature dependence of steady-State and presteady-state
kinetics of a type IIb Na+/Pi cotransporter.
J Membrane Biol, 2007, 215,8192
Institute of Physiology and Center for Integrative Human Physiology,
University of Zurich, Zurich, Switzerland
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Discussion and Outlook
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“While the functions and purposes of a protein are invariant in biology, the view adopted
by biologists often evolves with time sculpted by prevailing database and interpretations”
[135]. PiT1 and PiT2 (Na+ -coupled phosphate transporters of the SLC20 family) have been
assigned varying roles and given different aliases since their discovery. Because mammalian
cells have not evolved mechanisms to welcome viral invaders on purpose, viruses exploit
ubiquitous cell surface proteins to enter the cell and replicate. As viral targets, PiT1 and
PiT2 were called “viral receptors” Glvr-1 and Ram-1, respectively. When these proteins
were found to mediate Na+ coupled Pi cotransport into cells, they were renamed like their
prokaryotic paralogs (PiT). Due to their ubiquitous distribution (investigated at mRNA level,
see fig. ??) PiT1 and PiT2 were considered to be phosphate house-keeping transporters. One
of the main findings of this thesis has been a redefinition of the role of PiT2 from that of
housekeeping to physiologically regulated proximal tubule phosphate reabsorption. In this
work a thorough characterization of the transport kinetics of one isoform (XlPiT1) was
performed and the renal localization and dietary regulation of a member of the SLC20 family
was reported for the first time.
Transport mechanism. The novel electrogenic kinetics of the members of the PiT family
present a contrasting view of Na+-driven Pi cotransport with respect to that of the well-
characterized members of the SLC34 family (NaPi-IIa/b), and these kinetic differences are
underscored by the lack of sequence homology at the molecular level.
The solute transport families SLC20 and SLC34 both mediate Na+/Pi cotransport through
different molecular mechanisms and they show a preference for one of the two Pi species
that are most abundant at physiological pH: PiT transporters prefer monovalent Pi (H2PO−4 )
in contrast to all three SLC34 family proteins that prefer divalent Pi (HPO2−4 ) [69,136,137].
NaPi II and NaPi III also differ in their substrate stoichiometry. NaPi-IIa and NaPi-IIb
transport three Na+ ions per transport cycle (see fig. 3.3), with the translocation of one net
positive charge, whereas NaPi-IIc only cotransports two Na+ ions and is electroneutral. Like
NaPi-IIc PiT also transports two Na+ ions per cycle (see fig. 7.2) but with one net positive
charge. These differences result in a large difference in Pi concentrating capacity (as shown
in Table 7.1), and the ability of a transport protein to create a substrate gradient across the
membrane.
The two families differ in their optimum pH range: PiT1, which prefers H2PO−4 has a
Vmax that is relatively insensitive to a large pH variation (6.2-8), whereas for NaPi-IIa and
b, which prefer HPO2−4 , the Vmax is significantly reduced for pH <8 [82,132].
A significant finding in this work was the insensitivity of XlPiT1 to phosphonoformic
acid (PFA). This contrasts with the behavior of NaPi-IIa, b, c, which all show significant
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inhibition by PFA under the same conditions. Oocytes expressing XlPiT1 show an invariant
32P uptake even after incubation with 6 mM of PFA and 0.1 mM Pi (Ravera, Stange, Forster,
unpublished: see fig. 7.1). When analyzed using two-electrode voltage clamp, oocytes ex-
pressing XlPiT1 do not present any reduction of Pi induced current in presence of PFA (up
to 6 mM). These data contrast to those of Villa-Bellosta et al. 2008 [138] who characterized
the inhibition by PFA on PiT1 and PiT2 by 32P uptake. Oocytes expressing rat PiT2 show
a reduced 32P uptake in presence of 6 mM of PFA and 0.1 mM Pi compared to those exposed
only to 0.1 mM Pi. However for PFA concentration > 1 mM, an endogenous leak can be
induced in oocytes. This would have the effect of reducing the membrane potential and the
driving force for cotransport, which could result in an apparent inhibition by PFA.
Figure 7.1: The effect of PFA on 32P uptake in oocytes expressing XlPiT1 and ratPiT2, NI = non injected.
The difference in preferred Pi species can also explain why PFA inhibits Pi transport by
SLC34, but not by SLC20, because under physiological conditions PFA is a divalent anion.
It appears that in contrast to SLC34 proteins, Li+ can substitute for Na+ as the driving
cation, although the Pi induced currents are only 10% of those recorded with Na+. Moreover,
arsenate can also substitute for Pi as the driven substrate. Like SLC34 proteins, PiT1 and 2
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also may provide a pathway for arsenate to enter the cell and exert its toxic effects.
The voltage dependence of PiT requires that at least one partial reaction in the trans-
port cycle is membrane voltage (Vm) dependent. This implies that mobile charges must
sense the Vm, for example charged amino acid residues intrinsic to the protein or charged
substrates (e.g., Na+) moving within the transmembrane electric field. For example, the de-
crease of KNa0.5 with hyperpolarizing potentials (Fig. 4F in Ravera et al. 2007 [132]) suggests
that Na+ interaction with the transporter is voltage dependent, whereby a more negative Vm
would increase the likelihood of Na+ binding. The lack of detectable pre-steady-state cur-
rents in SLC20 prevents assigning voltage dependence to any particular step in the transport
cycle, unlike for NaPi-IIa and -IIb [132].
Our substrate-dependence data strongly suggest for XlPiT-1 an ordered binding for
the substrates, as indicated by the dependence of KPi0.5 on Na
+ concentration and KNa0.5 on Pi
(Fig.3 in Ravera et al. 2007 [132]). We hypothesize that a Na+ ion is the first to bind (see fig.
7.2). For Pi as the variable substrate, the dependence of ImaxPi on Na
+ is consistent with Na+
also being the last substrate to bind. Consistent with the 2:1 Na+:Pi stoichiometry, a possible
binding order, based on analogy with the electrogenic SLC34 transporters, might therefore
be Na+:H2PO−4 :Na
+. The increase in apparent cooperativity for Na+ interaction observed at
pH 8.0 would also support this scheme, whereby the decreased availability of H2PO−4 at pH
8.0 would increase the apparent dissociation constant associated with the proposed first Na+-
binding step, thus conferring a greater cooperativity to the overall Na+ interaction. On the
other hand, the Vmax effect observed for Pi, with Na+ as the variable substrate, would not be
consistent with this scheme and suggests that a more complex binding/debinding mechanism
exists that may involve both ordered and random partial reactions (see fig. 7.2) [82].
Figure 7.2: Proposed transport mechanism scheme for PiT1 from Virkki et al.2007 [82].
Because NaPi-IIc and PiT transport only 2 Na+ ions, less Na+ is loaded into the cell
and less energy is required to maintain the cell’s negative membrane potential, resulting in a
reduced energetic cost of transporting Pi.
The following table summarizes some of the features of the SLC34 and SLC20 members.
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Substrates Stoichiometry Electrogenic Concentrating PFA inhibition
Na+:Pi: Q Capacity
NaPi-IIa Na+, HPO2−4 , Arsenate 3:1:1 Yes 10,000 Yes
NaPi-IIb Na+, HPO2−4 , Arsenate 3:1:1 Yes 10,000 Yes
NaPi-IIc Na+, HPO2−4 , Arsenate 2:1:0 No 100 Yes
PiT-1 Na+, H2PO−4 , Li
+, Arsenate 2:1:1 Yes 1,000 No
PiT-2 Na+, H2PO−4 , Li
+, Arsenate 2:1:1 Yes 1,000 No
Table 7.1: Main differences between the SLC34 and SLC20 family members, adapted from Virkki et al.
2007 [82].
Kidney localization and physiological regulation. Three important findings have
emerged from this study on expression levels and regulation of PiT2 in the kidney: first,
the localization of PiT-2 to the apical brush border, in contrast with the proposal that
PiTs are all basolaterally located. Tenenhouse and co-workers reported that NaPi-IIc pro-
tein is significantly upregulated in mice homozygous for the disrupted NaPi-IIa gene [79]
and that NaPi-IIc protein is highly upregulated in Npt2−/− mice and accounts for residual
BBM Na+/Pi cotransport in this mutant model. The hypothesis of a third phosphate trans-
porter in the kidney BBM was made possible by the finding that PiT proteins are insensitive
to PFA. Second, switching from a low to high dietary phosphate suppresses NaPi-IIa/c-
mediated transport (PFA sensitive) by 32% and PiT2-mediated transport (PFA insensitive)
by 73%, suggesting that Pit-2 is a highly regulated protein. Third, the three players of apical
phosphate reuptake (NaPi-IIa/c and PiT-2) adapt to changes in dietary phosphate via pro-
tein re-distribution differently from PiT-2 wich shows an intermediate time course between
NaPi-IIa and NaPi-IIc .
By performing 32P uptake assays on brush border membrane vesicle preparation from
rats that had been conditioned on high or low Pi diets, we could distinguish between a “PFA
sensitive” and a “PFA-insensitive” component of Pi transport. One candidate for the “PFA-
insensitive” component would be PiT2, which was shown by immunohistochemistry and
western blot to be expressed and regulated by dietary Pi. Immunoblot analysis demonstrated
a clear difference in the time course of down regulation of PiT2 protein compared with NaPi-
IIa and NaPi-IIc.
That the time course of regulation of PiT2 in response to a switch between high and
low Pi diet and vice versa is different from both NaPi-IIa and NaPi-IIc, suggests a different
regulatory pathway. We can speculate that PiT2 might play a role in fine tuning overall Pi
reabsorption under different dietary conditions. Another potential and unique role for PiT2
in the kidney come from a consideration of the kinetic properties of SLC20 proteins [132]
and the related malaria plasmodium Falciparum PfPiT [121], expressed in Xenopus oocytes.
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The transport of either Pi species across a membrane will affect the pH, as it shifts the
equilibrium of the reaction H2PO−4 
 HPO2−4 +H+. Since PiT proteins transport H2PO−4 ,
we would expect that this would cause a concomitant acid loading of the cell. In contrast,
type II Na+/Pi cotransporters, which mediate HPO2−4 transport, would alkalinize the cell.
Whether the transport rates of type II or type III Na+/Pi cotransporters in their natural
environments are high enough to affect cell pH is not known. Our own experience with
expressing type II and type III Na+/Pi cotransporters in Xenopus oocytes would suggest
that the pH changes would be insignificant.
About 70% of filtered Pi is reabsorbed in the kidney proximal tubule. If we hypothesize
that only the type II Na+/Pi cotransporters are present, considering a glomerular filtration
rate of 180 L/day, a serum Pi concentration of 1 mM and a pH of 7.4 in the lumen of the
proximal tubule, since H2PO−4 remains, we can estimate an effective secretion of 40 mmoles
of H+ per day in the proximal tubular lumen. That PiT2 is also in the proximal tubular
brush border membrane, may constitute one more means to effect the regulation of the acid
loading in the proximal tubule [139].
The existence of multiple transporters for the same substrate in the proximal apical
membrane s not unusual. Apical H+ extrusion utilizes the multi-subunit H+-ATPase and
two Na+ /H+ exchanger isoforms and glucose uptake involves at least two isoforms. The
diverse characteristic of the transporters serves to ensure flexible substrate specificity as
well as multiple mechanisms and kinetics of transport regulation, which would be difficult
to achieve by a single transporter. Axial changes in luminal potential difference and Na+
concentration are minimal but changes in luminal pH and total phosphate concentrations are
large: early to late proximal tubule: pH 7.4 - 6.8, [Pi] 1.4 - 0.4 mM.
Micropuncture studies have shown that the pH in the proximal tubule can fall by up to
0.78 pH units relative to arterial blood in rats previously loaded with NH4Cl [140]. At pH 7.4,
the ratio [HPO2−4 ]/[H2PO
−
4 ] = 4, which decreases to 1.6 at pH 6.6, at which the NaPi-IIa/c
transport rate will be reduced by 50% [59, 82]. Because we expect PiT2 transport activity
to be unaffected by changes in luminal pH, to have a different regulation pathway compared
to the type II of NaPi, and a preference for different phosphate species, the presence of
both types of transporter may be necessary to ensure the complete Pi reabsorption from the
primary urine.
Structure-function studies. Knowing the structure of a transporter is essential to un-
derstand its mechanisms and possible interactions with accessory proteins, and physiological
regulation. Unfortunately, no crystal structure of Pit1 & 2 or their bacterial homologs is
available, and information about the structure-function relationships is insufficient to build
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a structural model.
From the analysis of the sequence of the SLC34 members it appears that there is an
inverted repeated motif, common to the Na+-coupled cotransporters. Also XlPiT1 shows an
internal repeated motif in the sequence as shown by Salau¨n et al.2001 [126] (blue region in
fig.3.8). This repeated motif is important because it could be involved in the coordination of
the substrates during their translocation across the membrane. The crystal structure of the
leucine transporter (LeuT) [33] shows a repeated motif which is involved in the substrate-
binding, and this has been observed also for the glucose transporter vSGLT1 [141] and for
the serotonine transporter SERT [47].
We proposed a topology model based on in silico investigations: hydrophathy analysis,
secondary structure prediction analysis, motif scans and we adopted these predictions using
data found in the literature. We started to validate our model by investigating the surface
accessibility. We began with the first predicted extracellular loop that we hypothesize to be,
first accessible from the external solution, second involved in the substrates coordination.
We based our assumption on experimental data about the same region in PiT2 expressed in
cell culture. This region is highly conserved among species and two charged residues Glu-
87 and Asp-95 correspond to residues in PiT2 that if mutated show a 8-16 times reduced
32P uptake [131]. SCAM allowed us to evaluate each residues in this region by comparing
the mutants behavior with the wild type one as shown for example by Lambert et al. for
NaPi-IIa [37]. We screened the mutants by 32P uptake and two-electrode voltage clamp. Our
data are preliminary, but so far we can confirm that part of this region is accessible from the
external solution. Some of the mutants show a reduction in the Pi-induced current and 32P
uptake after incubation with MTSET ([2-(trimethylammonium)ethyl]methanethio-sulfonate)
suggesting that the residues in that area are important in the binding of the substrates, the
labelling could reduce access to the substrate binding site or impede transitions between
conformational changes during the transport cycle. Some of the mutants show an increase in
the 32P uptake in presence of MTSET suggesting that area can be close to binding site and
can allow a larger volume due to the presence of the thiol reagent. The rates of the reaction
between the MTS reagent and the cysteines introduced in different positions are different and
this indicates a variations accessibility. Some of the mutants show a different apparent Pi
affinity compared with the wild type, such as mutant S86C, or a different voltage dependence
like the R90C or I93C or V96C, suggesting the importance of these sites in determining the
voltage dependent kinetics.
Outlook
There are many open questions that will need consideration in future studies:
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• transport mechanism - It will be important to define the precise binding order for
substrate and co-substrate. To have more information about the transport mechanism
of PiT will be useful to find PiT-specific inhibitors; one possible strategy would be to
investigate monovalent Pi derivatives.
• localization and physiological regulation - Adaptation of renal Pi handling
in response to changing dietary Pi is well-documented, yet the systemic and local sig-
naling pathways remain to be elucidated. From the systemic viewpoint, one might
hypothesize that a Pi sensor is involved, which would require identification. Other fac-
tor influences the phosphate reabsorption regulation in the kidney acting on NaPi type
II like PTH, vitamin D, FGF23 etc. All these factors are potential effectors of the PiT
level regulation.
• structure-function - Screening of substrate apparent affinity and of voltage depen-
dence needs to be completed to better understand the importance of the first predicted
extracellular loop in the interaction with the substrates, the identification of a putative
voltage sensor, and to elucidate the secondary structure of this region predicted from
MTS accessibility. Based on our topology model, XlPiT1 presents, charged residues
in the transmembrane field, these residues are potential candidates for the interaction
with the substrates and the study of mutations at these sites could provide important
information about the transport mechanism and the structure of the transporter.
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